Pfizer's other drug products are still 'underappreciated': Analyst

Dr. Vamil Divan of Mizuho Securities expects further upside for Pfizer's stock, which he says is trading at a significant discount. He adds that products outside of its coronavirus vaccine have shown signs of success, but says Pfizer needs to deliver more on the R&D side.